All In Biotech

Drug Trial Radar · NCT05158491

Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLC

Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With Small Cell Lung Cancer

Last checked: Nov 20, 2026Latest source record: Jan 5, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

63

Planned (sponsor's estimate)

Start

Nov 11, 2021

Primary completion

Dec 31, 2022

Study completion Mar 31, 2023

Sponsor

Lead sponsor
JenKem Technology Co., Ltd.Industry
Sponsor type
Industry
Collaborators
Peking University Cancer Hospital & Institute
First posted
Dec 15, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Sequential
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical trial is to evaluate the safety, tolerability and primary efficacy of JK-1201I in patients with small cell lung cancer (SCLC)

Conditions

  • Small Cell Lung Cancer (SCLC)

Interventions

  • JK-1201IDrug

    JK-1201I will be given every 3 weeks, maximum of 4 treatment cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine dose limited toxicity (DLT) of JK-1201I in patients with SCLC.Time frame: 21days
  2. To determine the maximum tolerance dose level of JK-1201I in patients with SCLC.Time frame: 21days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Beijing Cancer Hospital

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.